WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Nycomed

NycomedNycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.

Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy.

Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets.

Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion.

www.nycomed.com

Nycomed RSS Channel

Filters
List of articles in category Nycomed
Title Published Date
Nycomed to acquire local portfolio from Sanofi-Aventis and Zentiva 03 August 2009
Nycomed announces FDA filing for Daxas® in COPD 21 July 2009
Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission 20 June 2009
Nycomed Reports a Solid Start to 2009 28 May 2009
Nycomed files European marketing authorisation application for Daxas® 11 May 2009
Nycomed reports a satisfactory 2008 24 February 2009
Nycomed strengthens its osteoporosis portfolio 15 January 2009
Nycomed optimises its European manufacturing network 24 September 2008
Nycomed - strong results in second quarter 2008 19 August 2008
Nycomed's preclinical anti-cancer program sold to Bayer Schering Pharma 08 August 2008
Nycomed sells oncology programs to 4SC 05 June 2008
A promising start into 2008 for Nycomed 21 May 2008
Nycomed intends to move chemical production to Indian joint venture 11 March 2008
A successful 2007 paves the way for future of Nycomed 10 March 2008
Nycomed creates a leading specialty pharmaceutical player in dermatology 23 February 2008
Nycomed and Wyeth announce launch of an own generic version of PROTONIX® 30 January 2008
Nycomed significantly increases profitability 20 November 2007
Nycomed signs definitive agreement to acquire Bradley Pharmaceuticals, Inc. 30 October 2007
Nycomed and NPS Pharmaceuticals Announce Licensing Agreement for GATTEX™ 27 September 2007
  • Start
  • Prev
  • 1
  • 2
  • Next
  • End

Business & Industry

  • Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
  • Pfizer to acquire Global Blood Therapeutics for $5.4 billion to enhance presence in rare hematology
  • Roche's subcutaneous formulation of Tecentriq demonstrates positive Phase III results
  • Bayer Consumer Health leaders propose new principles for science-led self-care
  • GSK signs agreement to support pandemic preparedness in Europe

Research & Development

  • New method of nasal vaccine delivery could lead to better vaccines for HIV and COVID-19
  • Research identifies, exploits vulnerability in certain high-risk cancers
  • Scientists create long-acting injectable drug delivery system for tuberculosis
  • Treating cancer by sticking cells in place
  • Vitamin K prevents cell death: a new function for a long-known molecule
  • Disparities in United States COVID-19 vaccine distribution
  • New needle-free nasal vaccine shows promise for COVID-19

Conferences & Events

  • New approach to treatment of deadly kidney cancer
  • SAE Media Group proudly presents the 2nd Annual Aseptic Processing Conference
  • Pharma join together to achieve new standards in digital and patient innovation for clinical transformation
  • SMi's 22nd Annual Pain Therapeutics Conference
  • SMi Group Introduces the 4th Annual Injectable Drug Delivery Conference 2022
  • SMi's 5th Annual Pharmaceutical Microbiology East Coast Conference
  • SMi's 3rd Annual AI in Drug Discovery Conference

Regulatory Affairs

  • FDA approves first systemic treatment for alopecia areata
  • FDA urges drug manufacturers to develop risk management plans to promote a dtronger, resilient drug supply chain
  • FDA limits use of Janssen COVID-19 vaccine to certain individuals
  • EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice
  • FDA approves first generic of Symbicort to treat asthma and COPD
  1. You are here:  
  2. Home
  3. Nycomed

About

  • Home
  • Advertise
  • Privacy
  • Cookie Preferences
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2022. All Rights Reserved.